CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) have earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.60.

Several equities research analysts have recently commented on CAMP shares. Weiss Ratings downgraded shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Leerink Partners raised their target price on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. Rodman & Renshaw began coverage on shares of CAMP4 Therapeutics in a report on Tuesday, April 14th. They set a “buy” rating and a $7.00 target price for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a report on Friday, March 6th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of CAMP4 Therapeutics during the fourth quarter worth $61,000. Jefferies Financial Group Inc. purchased a new position in shares of CAMP4 Therapeutics during the fourth quarter worth $70,000. State Street Corp raised its holdings in shares of CAMP4 Therapeutics by 52.7% during the fourth quarter. State Street Corp now owns 39,700 shares of the Wireless communications provider’s stock worth $243,000 after purchasing an additional 13,700 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of CAMP4 Therapeutics during the fourth quarter worth $86,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in CAMP4 Therapeutics in the fourth quarter valued at $115,000.

CAMP4 Therapeutics Trading Up 2.7%

NASDAQ:CAMP opened at $4.21 on Thursday. CAMP4 Therapeutics has a 12 month low of $1.30 and a 12 month high of $7.75. The firm has a fifty day simple moving average of $4.49 and a 200-day simple moving average of $4.67. The company has a market capitalization of $218.63 million, a P/E ratio of -1.78 and a beta of 0.04.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%.The company had revenue of $1.29 million for the quarter. Equities analysts forecast that CAMP4 Therapeutics will post -0.8 EPS for the current year.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.